EORTC Bladder Cancer Recurrence and Progression Risk Calculator

Your details

Total number of tumors identified at TURBT.
Maximum diameter of the largest tumor at TURBT.
Recurrence rate in the year before the current TURBT. Select primary if this is the first diagnosis.
Pathologic tumor stage from TURBT specimen.
Whether concomitant flat carcinoma in situ was found alongside the papillary tumor.
Histologic grade using the 1973 WHO three-tier classification (G1, G2, G3). This is the grading system used in the original Sylvester 2006 study.
Recurrence scoreLow recurrence & progression risk
0points

Total EORTC recurrence risk score (0-17)

Progression score0points
1-year recurrence probability15%
5-year recurrence probability31%
1-year progression probability0.2%
5-year progression probability1%
Recurrence risk categoryLow risk
Progression risk categoryLow risk
0 pts
Low risk<1Intermediate (lower)1-5Intermediate (higher)5-10High risk10+
0 pts
Low risk<1Low-intermediate1-7Intermediate-high7-14High risk14+

EORTC recurrence score 0, progression score 0.

  • Recurrence score 0/17 places this patient in the "Low risk" band: approximately 15% chance of recurrence at 1 year and 31% at 5 years.
  • Progression score 0/23 places this patient in the "Low risk" band: approximately 0.2% chance of progression to muscle-invasive disease at 1 year and 0.8% at 5 years.
  • No high-risk features identified. Single-dose intravesical mitomycin C immediately after TURBT is typically recommended for low-risk cases.
  • These probabilities are population-level estimates from seven EORTC clinical trials. Individual outcomes depend on additional factors including age, performance status, and response to intravesical therapy.

Next stepLow to low-intermediate progression risk. Discuss intravesical chemotherapy options and cystoscopy surveillance schedule with your urologist.

 = Powered by OnlyCalculators